Key Points
- Director James Foster sold 75,000 shares of Charles River Laboratories International on June 29 at an average price of $225, totaling about $16.9 million. The sale reduced his direct holdings by more than 70% and was made under a pre-arranged Rule 10b5-1 plan.
- CRL shares were trading higher, opening at $229.13 and sitting near the top of their 12-month range of $144.26 to $236.62. The company has a market value of about $11.04 billion.
- The company recently reported better-than-expected quarterly earnings, posting $2.06 EPS versus the $1.96 estimate and revenue of $995.83 million. Analysts currently rate the stock Moderate Buy with an average price target of $215.88.
Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) Director James Foster sold 75,000 shares of Charles River Laboratories International stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the transaction, the director directly owned 31,596 shares in the company, valued at approximately $7,109,100. The trade was a 70.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Charles River Laboratories International Trading Up 1.0%
Charles River Laboratories International stock opened at $229.13 on Thursday. Charles River Laboratories International, Inc. has a 12-month low of $144.26 and a 12-month high of $236.62. The firm has a market capitalization of $11.04 billion, a price-to-earnings ratio of -60.94, a P/E/G ratio of 2.59 and a beta of 1.39. The firm has a 50 day moving average of $179.65 and a 200 day moving average of $184.08. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.10. The business had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, research analysts predict that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research firms have commented on CRL. Royal Bank Of Canada assumed coverage on Charles River Laboratories International in a report on Tuesday, April 14th. They set an "outperform" rating and a $215.00 price target on the stock. Morgan Stanley raised Charles River Laboratories International from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $185.00 to $220.00 in a research note on Wednesday, June 17th. Sanford C. Bernstein set a $250.00 target price on Charles River Laboratories International in a research note on Wednesday. Mizuho set a $192.00 price target on Charles River Laboratories International in a report on Friday, May 8th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a "neutral" rating on the stock in a research report on Monday, April 13th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $215.88.
Check Out Our Latest Stock Report on Charles River Laboratories International
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in CRL. Jones Financial Companies Lllp lifted its stake in shares of Charles River Laboratories International by 167.6% in the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company's stock valued at $253,000 after purchasing an additional 1,074 shares during the last quarter. Empowered Funds LLC purchased a new stake in Charles River Laboratories International during the 1st quarter valued at $418,000. American Century Companies Inc. raised its holdings in Charles River Laboratories International by 41.9% during the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company's stock valued at $830,000 after buying an additional 1,616 shares during the period. Brown Advisory Inc. lifted its position in Charles River Laboratories International by 5.1% in the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company's stock worth $354,000 after buying an additional 114 shares during the last quarter. Finally, California Public Employees Retirement System boosted its stake in Charles River Laboratories International by 3.9% during the second quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company's stock worth $12,837,000 after buying an additional 3,198 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.
About Charles River Laboratories International
(
Get Free Report)
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
